439 related articles for article (PubMed ID: 28526184)
1. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Staels B
Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Staels B
Am J Cardiol; 2017 Jul; 120(1S):S28-S36. PubMed ID: 28606341
[TBL] [Abstract][Full Text] [Related]
3. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton R
Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
[TBL] [Abstract][Full Text] [Related]
4. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
[TBL] [Abstract][Full Text] [Related]
5. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
[TBL] [Abstract][Full Text] [Related]
6. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345
[TBL] [Abstract][Full Text] [Related]
7. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
[TBL] [Abstract][Full Text] [Related]
8. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
[TBL] [Abstract][Full Text] [Related]
9. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
Jørgensen NB; Pedersen J; Vaag AA
J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
[No Abstract] [Full Text] [Related]
10. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
11. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Rajasekeran H; Lytvyn Y; Cherney DZ
Kidney Int; 2016 Mar; 89(3):524-6. PubMed ID: 26880444
[TBL] [Abstract][Full Text] [Related]
13. The EMPA-REG study: What has it told us? A diabetologist's perspective.
DeFronzo RA
J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076
[No Abstract] [Full Text] [Related]
14. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
DeFronzo RA; Chilton R; Norton L; Clarke G; Ryder RE; Abdul-Ghani M
Diabetes Obes Metab; 2016 May; 18(5):454-62. PubMed ID: 26919068
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms linking empagliflozin to cardiovascular and renal protection.
Perrone-Filardi P; Avogaro A; Bonora E; Colivicchi F; Fioretto P; Maggioni AP; Sesti G; Ferrannini E
Int J Cardiol; 2017 Aug; 241():450-456. PubMed ID: 28395981
[TBL] [Abstract][Full Text] [Related]
17. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
Luconi M; Raimondi L; Di Franco A; Mannucci E
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1071-1078. PubMed ID: 27776917
[TBL] [Abstract][Full Text] [Related]
18. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
Scheen AJ
Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
[TBL] [Abstract][Full Text] [Related]
19. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Scheen AJ; Piérard L; Krzesinski JM; Paquot N
Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
[TBL] [Abstract][Full Text] [Related]
20. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
Scheen AJ; Wallemacq C; Jandrain B; Ernest P
Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]